Even when insulin is used, these classes of medications still provide benefits. Joanna Khatib In a meta-analysis, Khatib and colleagues assessed major adverse CV events from eight recent CV outcome trials for SGLT2 inhibitors, GLP-1 receptor agonists and DPP-IV inhibitors: DECLARE, EMPA-REG, EXSCEL, HARMONY, LEADER, SUSTAIN-6, EXAMINE and SAVOR-TIMI 53
Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P et al
Tracking via UPS and GobyMeds email
This combination is known as a twincretin
Someone taking 1.7 mg weekly who cannot tolerate the post-injection nausea might switch to 0.85 mg on Monday and 0.85 mg on Thursday